NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals Inc (NASDAQ:AGIO) released its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, beating analysts' consensus estimates of ($1.72) by $0.12. The biopharmaceutical company earned $35.44 million during the quarter, compared to analyst estimates of $33.72 million. Agios Pharmaceuticals had a negative return on equity of 77.09% and a negative net margin of 348.96%. Agios Pharmaceuticals's revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.58) EPS. View Agios Pharmaceuticals' Earnings History.

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Agios Pharmaceuticals.

11 analysts have issued 1-year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $79.00. On average, they expect Agios Pharmaceuticals' stock price to reach $64.56 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Media coverage about AGIO stock has trended somewhat positive on Monday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO) and Ascendis Pharma A/S (ASND).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Alibaba Group (BABA), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV) and Micron Technology (MU).

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (14.99%), State Street Corp (3.20%), First Trust Advisors LP (2.60%), Farallon Capital Management LLC (2.12%), ArrowMark Colorado Holdings LLC (1.88%) and Perceptive Advisors LLC (1.53%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Casdin Capital LLC, Handelsbanken Fonder AB, Rhenman & Partners Asset Management AB, New York State Common Retirement Fund, Rafferty Asset Management LLC, Alyeska Investment Group L.P. and Bank of Montreal Can. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

AGIO stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Perceptive Advisors LLC, First Trust Advisors LP, Bank of America Corp DE, Marshall Wace LLP, UBS Asset Management Americas Inc., Cadian Capital Management LP and ArrowMark Colorado Holdings LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $51.51.

Agios Pharmaceuticals has a market capitalization of $3.03 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]